Infectious diseases can be caused by various pathogenic
microorganisms such as bacteria, fungi, parasites, or viruses. These diseases
can be transmitted from one individual to another through either direct contact
or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the
growth (static) of infectious agents. Based on the target organism, anti-infective
drugs can be categorized into antibacterial, antiviral, antifungal, and
antiparasitic. Anti-infective drugs can act via host defence system or can
directly target the causative agent.
Analysts forecast the Global Infectious Disease Treatment
market to grow at a CAGR of 3.43 percent over the period 2013-2018.
The Report recognizes the following companies as the key
players in the Global Infectious Disease Treatment Market: F. Hoffmann-La Roche
Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck
& Co. Inc. and Pfizer Inc.
Other Prominent Vendors in the market are: AbbVie, Astellas
Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb,
Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi
Tanabe Pharma, Novartis, pSivida and Sanofi.
One of the emerging trends in this market is the emergence
of Interferon-free regimens. Various all-oral, IFN-free regimens are under
development and are expected to attain higher sustained virologic response and
cause fewer side effects than the currently approved therapies.
Inquire on the Report
at http://www.sandlerresearch.org/inquire-before-buying?rname=22745
Covered in this Report
This report covers the present scenario and the growth
prospects of the Global Infectious Disease Treatment market for the period
2014-2018. To calculate the market size, the report considers the revenue
generated through the sales of various drugs administered to treat various
infectious diseases caused by bacteria, virus, fungi, and parasites, which
include:
- Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials)
- Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals)
- Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs)
- Antiparasitic drugs
Global Infectious Disease Treatment Market 2014-2018, has
been prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the Americas, and the EMEA and APAC regions; it also
covers the Global Infectious Disease Treatment market landscape and its growth
prospects in the coming years. The report also includes a discussion of the key
vendors operating in this market. According to the report, the launch of
Direct-acting Antivirals is one of the major drivers for the Global Infectious
Disease Treatment market. DAAs are administered in combination with other
antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of
treatment and decrease the duration of therapy and this leads to increased
preference for this treatment among patients.
Further, the report states that a generic erosion of
marketed drugs is one of the major challenges faced by the market. A loss of
patent protection and market exclusivity generally triggers the entry of
low-cost alternatives for drugs, which, in turn, decreases the sales of
innovator-approved drugs.
Get discount on the
Report at http://www.sandlerresearch.org/discount?rname=22745
